ProPhase Labs Inc (PRPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ProPhase Labs Inc (PRPH) has a cash flow conversion efficiency ratio of 0.025x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-78.00K) by net assets ($-3.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ProPhase Labs Inc stock valuation for the company's overall valuation and market capitalisation.
ProPhase Labs Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how ProPhase Labs Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ProPhase Labs Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProPhase Labs Inc ranked by their cash flow conversion efficiency. Explore ProPhase Labs Inc (PRPH) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aquila Energy Efficiency Trust PLC
LSE:AEET
|
-0.027x |
|
Dianomi PLC
LSE:DNM
|
-0.364x |
|
Veg of Lund AB
ST:VOLAB
|
-0.083x |
|
RT Minerals Corp
V:RTM
|
-0.301x |
|
First Merchants Corporation Depository Shares
NASDAQ:FRMEP
|
0.033x |
|
Murray & Roberts Holdings Ltd
JSE:MUR
|
0.535x |
|
TARGA EXPLORATION CORP.
F:V6Y
|
N/A |
|
First Eagle Alternative Capital BDC Inc
NYSE:FCRX
|
0.022x |
Annual Cash Flow Conversion Efficiency for ProPhase Labs Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of ProPhase Labs Inc from 1996 to 2025. View ProPhase Labs Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.51 Million | $-8.34 Million | -2.379x | +0.28% |
| 2024-12-31 | $7.35 Million | $-17.54 Million | -2.385x | -937.94% |
| 2023-12-31 | $49.38 Million | $-11.35 Million | -0.230x | -151.21% |
| 2022-12-31 | $63.63 Million | $28.55 Million | 0.449x | +293.16% |
| 2021-12-31 | $58.63 Million | $-13.62 Million | -0.232x | +5.40% |
| 2020-12-31 | $10.56 Million | $-2.59 Million | -0.246x | -227.91% |
| 2019-12-31 | $11.23 Million | $-841.00K | -0.075x | +41.68% |
| 2018-12-31 | $16.50 Million | $-2.12 Million | -0.128x | -49.70% |
| 2017-12-31 | $33.09 Million | $-2.84 Million | -0.086x | -8.34% |
| 2016-12-31 | $5.96 Million | $-472.00K | -0.079x | +80.01% |
| 2015-12-31 | $8.83 Million | $-3.50 Million | -0.396x | -31.98% |
| 2014-12-31 | $10.72 Million | $-3.22 Million | -0.300x | -432.47% |
| 2013-12-31 | $12.60 Million | $1.14 Million | 0.090x | +118.04% |
| 2012-12-31 | $11.45 Million | $-5.73 Million | -0.500x | -166.43% |
| 2011-12-31 | $11.23 Million | $-2.11 Million | -0.188x | +28.78% |
| 2010-12-31 | $13.46 Million | $-3.55 Million | -0.264x | -933.02% |
| 2009-12-31 | $14.06 Million | $445.00K | 0.032x | +118.40% |
| 2008-12-31 | $17.77 Million | $-3.06 Million | -0.172x | -205.56% |
| 2007-12-31 | $23.30 Million | $-1.31 Million | -0.056x | -250.57% |
| 2006-12-31 | $25.59 Million | $956.94K | 0.037x | -77.76% |
| 2005-12-31 | $25.37 Million | $4.27 Million | 0.168x | -20.79% |
| 2004-12-31 | $21.96 Million | $4.66 Million | 0.212x | +556.59% |
| 2003-12-31 | $20.79 Million | $-966.23K | -0.046x | -257.52% |
| 2002-12-31 | $18.42 Million | $543.64K | 0.030x | +156.01% |
| 2001-12-31 | $21.20 Million | $-1.12 Million | -0.053x | +40.24% |
| 2000-12-31 | $21.21 Million | $-1.87 Million | -0.088x | -277.69% |
| 1999-12-31 | $26.20 Million | $1.30 Million | 0.050x | -75.14% |
| 1998-12-31 | $44.60 Million | $8.90 Million | 0.200x | -7.54% |
| 1997-12-31 | $41.70 Million | $9.00 Million | 0.216x | +123.54% |
| 1996-12-31 | $1.20 Million | $-1.10 Million | -0.917x | -- |
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart … Read more